PGR and breast cancer: The estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) statuses of primary breast cancer tissue are used clinically to approximate biological subtypes, to predict outcome, and to guide therapy decisions, especially for endocrine and HER2-targeted regimens [4, 5].